Skye Bioscience Files 8-K
Ticker: SKYE · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1516551
Sentiment: neutral
Topics: corporate-filing, 8-k
TL;DR
Skye Bioscience filed an 8-K on 6/10/24. Nothing major, just standard reporting.
AI Summary
Skye Bioscience, Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements. The company, formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc., is incorporated in Nevada and headquartered in San Diego, California.
Why It Matters
This filing provides an official update on Skye Bioscience's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing that does not disclose any new material events or financial distress.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- June 10, 2024 (date) — Filing Date
- Nevada (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Principal Executive Offices
- Emerald Bioscience, Inc. (company) — Former Company Name
- Nemus Bioscience, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Skye Bioscience, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 10, 2024.
When was Skye Bioscience, Inc. incorporated and where are its principal executive offices located?
Skye Bioscience, Inc. was incorporated in Nevada and its principal executive offices are located at 11250 El Camino Real, Suite 100, San Diego, CA 92130.
What were Skye Bioscience, Inc.'s former company names?
Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
What is the SEC file number and IRS Employer Identification Number for Skye Bioscience, Inc.?
The SEC file number for Skye Bioscience, Inc. is 001-42009, and its IRS Employer Identification Number is 45-0692882.
What is the standard industrial classification for Skye Bioscience, Inc.?
The standard industrial classification for Skye Bioscience, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 805 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2024-06-10 09:27:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate
Filing Documents
- skye-20240610.htm (8-K) — 31KB
- a240610_skyexnrxsbip2atopl.htm (EX-99.1) — 16KB
- 0001516551-24-000059.txt ( ) — 174KB
- skye-20240610.xsd (EX-101.SCH) — 2KB
- skye-20240610_def.xml (EX-101.DEF) — 2KB
- skye-20240610_lab.xml (EX-101.LAB) — 21KB
- skye-20240610_pre.xml (EX-101.PRE) — 12KB
- skye-20240610_htm.xml (XML) — 2KB
01 Other Events
Item 8.01 Other Events. On June 10, 2024, Skye Bioscience, Inc. (the "Company," "we" and "our") issued a press release announcing that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering intraocular pressure. The Company intends to discontinue the clinical development of SBI-100 OE and all research and development associated with SBI-100 including its ophthalmology pipeline to direct its clinical development resources to its obesity program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The press release will also be available under the "Investors" section of the Company's website.
FORWARD LOOKING STATEMENTS
FORWARD LOOKING STATEMENTS This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and published findings, and expected operating runway. Such statements and other statements in this Current Report on Form 8-K that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the "Risk Factors" section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: June 10, 2024 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer